Multiple Stakeholders Benefit

  • Payers significantly reduce overall cost of care.

  • Patients receive early detection, early therapy, cancer risk reduction, and a more pleasant experience.

  • Physicians have more data to use to provide the best treatments for their patients and are able to diagnose cancer earlier when it is more likely to be curable.

  • Hospitals have more lab service revenue.

  • Investors can access a multi-Bn market in a relatively short period of time with a high margin, highly scalable screening test.

  • Cancer Research – more data provides more insights.

  • Big Pharma: ┬áDrug discovery efforts are improved by the use of rapid, low cost testing methods implemented during clinical trials.

  • Universities want to participate in research related to breath based diagnostics.